{"id":7224,"date":"2022-03-17T17:04:40","date_gmt":"2022-03-17T17:04:40","guid":{"rendered":"https:\/\/maat.swebwp.oci.eu\/?p=7224"},"modified":"2023-09-25T13:52:56","modified_gmt":"2023-09-25T13:52:56","slug":"maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt","status":"publish","type":"post","link":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/","title":{"rendered":"MaaT Pharma pr\u00e9sentera des donn\u00e9es cliniques prometteuses pour MaaT013, son candidat-m\u00e9dicament le plus avanc\u00e9, lors de la 48\u00e8me rencontre annuelle de l\u2019EBMT"},"content":{"rendered":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]\n<h3 style=\"text-align: center;\"><span style=\"color: #283583;\">MaaT Pharma pr\u00e9sentera des donn\u00e9es cliniques prometteuses pour MaaT013, son candidat-m\u00e9dicament le plus avanc\u00e9, lors de la 48<sup>\u00e8me<\/sup> rencontre annuelle de l\u2019EBMT<\/span><\/h3>\n[\/vc_column_text]<div class=\"nectar-fancy-ul\" data-list-icon=\"icon-salient-thin-line\" data-animation=\"false\" data-animation-delay=\"0\" data-color=\"accent-color\" data-spacing=\"default\" data-alignment=\"left\"> \n<ul>\n<li>Des donn\u00e9es issues de 76 patients atteints de la maladie aigu\u00eb du greffon contre l\u2019h\u00f4te (aGvH) et trait\u00e9s avec MaaT013 seront pr\u00e9sent\u00e9es.<\/li>\n<li>La pr\u00e9sentation orale soulignera le potentiel de MaaT013 \u00e0 am\u00e9liorer les chances de survie des patients souffrant de la maladie du greffon contre l\u2019h\u00f4te gastrointestinale aigu\u00eb (GI-aGvH).<\/li>\n<li>Ces donn\u00e9es ont \u00e9t\u00e9 pr\u00e9c\u00e9demment partag\u00e9es lors de la 63<sup>\u00e8me<\/sup> rencontre annuelle de l\u2019<em>American Society of Hematology<\/em> (ASH) en d\u00e9cembre 2021 et incluent les r\u00e9sultats de l\u2019essai de Phase II HERACLES sur 24 patients avec une aGvH de grade III-IV cortico-r\u00e9sistante \u00e0 pr\u00e9dominance gastro-intestinale et du programme d\u2019acc\u00e8s compassionnel en France chez 52 patients avec une aGvH pr\u00e9sentant une composante GI et n\u2019ayant pas r\u00e9pondu \u00e0 plusieurs lignes de traitement.<\/li>\n<\/ul>\n <\/div>[\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]<strong>Lyon, France, 17 mars 2022 \u2013 18h00 CET &#8211; <\/strong><a href=\"https:\/\/maat.swebwp.oci.eu\/\"><strong>MaaT Pharma<\/strong><\/a> <strong><span style=\"color: #283583;\">(EURONEXT\u00a0: MAAT \u2013 \u00ab\u00a0la Soci\u00e9t\u00e9\u00a0\u00bb)<\/span><\/strong><strong>,<\/strong> <strong><span style=\"color: #283583;\">soci\u00e9t\u00e9 fran\u00e7aise de biotechnologies en stade clinique avanc\u00e9, pionni\u00e8re dans le d\u00e9veloppement de m\u00e9dicaments dans la restauration du microbiote intestinal pour am\u00e9liorer la survie des patients atteints de cancers, <\/span><\/strong>annonce aujourd\u2019hui que des r\u00e9sultats prometteurs issus de son essai clinique de Phase 2 HERACLES (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03359980\">NCT03359980<\/a>, n=24) et de son programme d\u2019acc\u00e8s compassionnel (EAP, n=52) pour son candidat-m\u00e9dicament microbiote le plus avanc\u00e9, MaaT013, seront expos\u00e9s \u00e0 l\u2019occasion d\u2019une pr\u00e9sentation orale lors de la 48<sup>\u00e8me<\/sup> rencontre annuelle de l\u2019<em>European Society for Blood and Marrow Transplantation<\/em> (EBMT 2022), qui se tiendra virtuellement du 19 au 23 mars 2022.<\/p>\n<p>Les donn\u00e9es ont \u00e9t\u00e9 pr\u00e9sent\u00e9es \u00e0 l\u2019<a href=\"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presente-a-loccasion-de-la-63eme-rencontre-annuelle-de-lash-des-resultats-cliniques-prometteurs-issus-de-76-patients-atteints-de-la-maladie-du-greffon-contre-l\/\">American Society of Hematology en d\u00e9cembre 2021<\/a> et ont d\u00e9montr\u00e9 que le traitement par MaaT013 de patients ayant d\u00e9velopp\u00e9 une GI-aGvH \u00e0 la suite d\u2019une transplantation de cellules souches h\u00e9matopo\u00ef\u00e9tiques pr\u00e9sentait un taux de r\u00e9ponse gastro-intestinale globale (GI-ORR) prometteur dans les deux groupes. Le taux de r\u00e9ponse global GI-ORR observ\u00e9 au jour 28 \u00e9tait de 38% dans l\u2019essai HERACLES, dont 5 patients en r\u00e9ponse compl\u00e8te (21%)\u00a0et de 58% en EAP, dont 17 patients en r\u00e9ponse compl\u00e8te (33%). Le taux de survie \u00e0 12 mois pour les patients r\u00e9pondeurs au traitement \u00e9tait de 44% pour HERACLES et 59% pour l\u2019EAP.<\/p>\n<p>Les r\u00e9sultats seront pr\u00e9sent\u00e9s virtuellement et en direct par le <strong>docteur\u00a0Florent Malard<\/strong>, <strong>H\u00e9matologue \u00e0 l\u2019H\u00f4pital Saint-Antoine et professeur agr\u00e9g\u00e9 \u00e0 Sorbonne Universit\u00e9<\/strong>, qui a particip\u00e9 \u00e0 l\u2019essai clinique HERACLES.[\/vc_column_text][vc_column_text]<strong><span style=\"color: #283583;\">D\u00e9tails de la pr\u00e9sentation orale (session virtuelle en direct) :<\/span><\/strong><\/p>\n<ul>\n<li>Titre : Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase 2a Heracles Study and Expanded Access Program<\/li>\n<li>N\u00b0 d\u2019abstract : <a href=\"https:\/\/ebmt2022.abstractserver.com\/program\/#\/details\/presentations\/966\">OS10-06<\/a><\/li>\n<li>Nom de la session : Session Orale OS10: GVHD I, clinique<\/li>\n<li>Date\/ heure : Mercredi 23 mars de 9h45 \u00e0 9h54 CET<\/li>\n<li>Lien pour s\u2019inscrire : <a href=\"https:\/\/urlz.fr\/hHX6\">https:\/\/urlz.fr\/hHX6<\/a><\/li>\n<\/ul>\n[\/vc_column_text][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]<strong><span style=\"color: #283583;\">A propos de MaaT013<\/span><\/strong><\/p>\n<p>MaaT013 est une <em>Microbiome Ecosystem Therapy<\/em> (microbioth\u00e9rapie \u00e0 \u00e9cosyst\u00e8me complet) pr\u00eate \u00e0 l\u2019emploi, standardis\u00e9e et issue d\u2019une combinaison de microbiotes de donneurs sains. Le produit est caract\u00e9ris\u00e9 par une diversit\u00e9 et une richesse \u00e9lev\u00e9es et standardis\u00e9es des esp\u00e8ces microbiennes qu\u2019il contient et la pr\u00e9sence de Butycore<sup>TM<\/sup> (ensemble de bact\u00e9ries produisant des m\u00e9tabolites anti-inflammatoires). MaaT013 a pour but de restaurer la relation symbiotique entre le microbiote intestinal du patient et son syst\u00e8me immunitaire, afin de corriger la r\u00e9activit\u00e9 et restaurer la tol\u00e9rance des fonctions immunitaires MaaT013 a re\u00e7u la d\u00e9signation de m\u00e9dicament orphelin de la Food and Drug Administration (FDA) aux \u00c9tats-Unis et de l&rsquo;Agence europ\u00e9enne des m\u00e9dicaments (EMA) pour son d\u00e9veloppement dans le traitement de la maladie aig\u00fce du greffon contre l\u2019h\u00f4te (aGvH).[\/vc_column_text][vc_column_text]<strong><span style=\"color: #283583;\">A propos de MaaT Pharma<\/span><\/strong><\/p>\n<p>MaaT Pharma est une soci\u00e9t\u00e9 de biotechnologies au stade clinique qui a mis au point une approche compl\u00e8te pour restaurer la symbiose microbiote\/h\u00f4te des patients atteints de cancers. Engag\u00e9e dans le traitement des cancers et de la maladie du greffon contre l\u2019h\u00f4te (GvH), une complication grave survenant apr\u00e8s une greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques, MaaT Pharma a d\u00e9j\u00e0 r\u00e9alis\u00e9 la preuve de concept de son approche chez des patients atteints de GvH aigu\u00eb dans un essai clinique de Phase 2. Sa puissante plateforme de d\u00e9couverte et d\u2019analyse, gutPrint\u00ae, soutient le d\u00e9veloppement de son portefeuille de produits et son extension \u00e0 des indications plus larges en aidant \u00e0 d\u00e9terminer de nouvelles cibles th\u00e9rapeutiques, \u00e0 \u00e9valuer les m\u00e9dicaments candidats et \u00e0 identifier des biomarqueurs pour la prise en charge de pathologies impliquant le microbiote.<\/p>\n<p>Les th\u00e9rapies issues d\u2019un \u00e9cosyst\u00e8me microbien (<em>Microbiome Ecosystem Therapies<\/em>) sont toutes produites dans le cadre tr\u00e8s standardis\u00e9 d\u2019une fabrication et de contr\u00f4les qualit\u00e9 cGMP afin de garantir en toute s\u00e9curit\u00e9 l\u2019acc\u00e8s \u00e0 la diversit\u00e9 et la richesse du microbiote, sous forme orale ou de lavement. MaaT Pharma b\u00e9n\u00e9ficie de l\u2019engagement de scientifiques de renomm\u00e9e mondiale et de relations \u00e9tablies avec les instances r\u00e9glementaires pour faire progresser l\u2019int\u00e9gration des th\u00e9rapies \u00e0 base de microbiote dans la pratique clinique.<\/p>\n<p>MaaT Pharma est cot\u00e9e sur Euronext Paris (Code mn\u00e9monique\u00a0: MAAT).[\/vc_column_text][image_with_animation image_url=\u00a0\u00bb6212&Prime; animation=\u00a0\u00bbFade In\u00a0\u00bb hover_animation=\u00a0\u00bbnone\u00a0\u00bb alignment=\u00a0\u00bbcenter\u00a0\u00bb border_radius=\u00a0\u00bbnone\u00a0\u00bb box_shadow=\u00a0\u00bbnone\u00a0\u00bb image_loading=\u00a0\u00bbdefault\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb max_width_mobile=\u00a0\u00bbdefault\u00a0\u00bb][vc_column_text]<strong><span style=\"color: #283583;\">Donn\u00e9es prospectives <\/span><\/strong><\/p>\n<p>Ce communiqu\u00e9 de presse contient des d\u00e9clarations prospectives. Toutes les d\u00e9clarations autres que les \u00e9nonc\u00e9s de faits historiques inclus dans le pr\u00e9sent communiqu\u00e9 de presse au sujet d&rsquo;\u00e9v\u00e9nements futurs sont sujettes \u00e0 (i) des changements sans pr\u00e9avis et (ii) des facteurs ind\u00e9pendants de la volont\u00e9 de la Soci\u00e9t\u00e9. Ces d\u00e9clarations peuvent comprendre, sans s&rsquo;y limiter, tout \u00e9nonc\u00e9 pr\u00e9c\u00e9d\u00e9, suivi ou incluant des mots tels que \u00ab cibler \u00bb, \u00ab croire \u00bb, \u00ab s&rsquo;attendre \u00e0 \u00bb, \u00ab viser \u00bb, \u00ab avoir l&rsquo;intention de \u00bb, \u00ab pouvoir \u00bb, \u00ab pr\u00e9voir \u00bb, \u00ab estimer \u00bb, \u00ab planifier \u00bb, \u00ab projeter \u00bb, \u00ab vouloir \u00bb, \u00ab pouvoir avoir \u00bb, \u00ab susceptible de \u00bb, \u00ab probable \u00bb, \u00ab devoir \u00bb, \u00ab pr\u00e9visions \u00bb et d\u2019autres mots et termes ayant un sens similaire ou la forme n\u00e9gative qui en d\u00e9coule. Les d\u00e9clarations prospectives sont assujetties \u00e0 des risques et \u00e0 des incertitudes inh\u00e9rentes ind\u00e9pendants de la volont\u00e9 de la Soci\u00e9t\u00e9 qui pourraient conduire \u00e0 ce que les r\u00e9sultats ou les performances r\u00e9els de la Soci\u00e9t\u00e9 diff\u00e8rent consid\u00e9rablement des r\u00e9sultats ou des performances attendus exprim\u00e9s ou sous-entendus dans ces d\u00e9clarations prospectives.[\/vc_column_text][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_btn size=\u00a0\u00bblarge\u00a0\u00bb open_new_tab=\u00a0\u00bbtrue\u00a0\u00bb button_style=\u00a0\u00bbregular\u00a0\u00bb button_color_2=\u00a0\u00bbAccent-Color\u00a0\u00bb icon_family=\u00a0\u00bbnone\u00a0\u00bb text=\u00a0\u00bbT\u00e9l\u00e9charger le communiqu\u00e9 de presse\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2022\/03\/220302-MaaT013-EBMT-Curtain-Raiser-FR-VF-2.pdf\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"<p>[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb&#8230;<\/p>\n","protected":false},"author":2,"featured_media":7120,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[],"year_press":[48],"class_list":{"0":"post-7224","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-communiques-de-presse-fr","8":"year_press-48"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MaaT Pharma pr\u00e9sentera des donn\u00e9es cliniques prometteuses pour MaaT013, son candidat-m\u00e9dicament le plus avanc\u00e9, lors de la 48\u00e8me rencontre annuelle de l\u2019EBMT - MaaT Pharma<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaaT Pharma pr\u00e9sentera des donn\u00e9es cliniques prometteuses pour MaaT013, son candidat-m\u00e9dicament le plus avanc\u00e9, lors de la 48\u00e8me rencontre annuelle de l\u2019EBMT - MaaT Pharma\" \/>\n<meta property=\"og:description\" content=\"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/\" \/>\n<meta property=\"og:site_name\" content=\"MaaT Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-17T17:04:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-25T13:52:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2362\" \/>\n\t<meta property=\"og:image:height\" content=\"2362\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"MaaT Pharma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"MaaT Pharma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/\"},\"author\":{\"name\":\"MaaT Pharma\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"MaaT Pharma pr\u00e9sentera des donn\u00e9es cliniques prometteuses pour MaaT013, son candidat-m\u00e9dicament le plus avanc\u00e9, lors de la 48\u00e8me rencontre annuelle de l\u2019EBMT\",\"datePublished\":\"2022-03-17T17:04:40+00:00\",\"dateModified\":\"2023-09-25T13:52:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/\"},\"wordCount\":2294,\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/\",\"name\":\"MaaT Pharma pr\u00e9sentera des donn\u00e9es cliniques prometteuses pour MaaT013, son candidat-m\u00e9dicament le plus avanc\u00e9, lors de la 48\u00e8me rencontre annuelle de l\u2019EBMT - MaaT Pharma\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\",\"datePublished\":\"2022-03-17T17:04:40+00:00\",\"dateModified\":\"2023-09-25T13:52:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/#primaryimage\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\",\"contentUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/maat.swebwp.oci.eu\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma pr\u00e9sentera des donn\u00e9es cliniques prometteuses pour MaaT013, son candidat-m\u00e9dicament le plus avanc\u00e9, lors de la 48\u00e8me rencontre annuelle de l\u2019EBMT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"name\":\"MaaT Pharma\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"MaaT Pharma\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaaT Pharma pr\u00e9sentera des donn\u00e9es cliniques prometteuses pour MaaT013, son candidat-m\u00e9dicament le plus avanc\u00e9, lors de la 48\u00e8me rencontre annuelle de l\u2019EBMT - MaaT Pharma","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"MaaT Pharma pr\u00e9sentera des donn\u00e9es cliniques prometteuses pour MaaT013, son candidat-m\u00e9dicament le plus avanc\u00e9, lors de la 48\u00e8me rencontre annuelle de l\u2019EBMT - MaaT Pharma","og_description":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb...","og_url":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/","og_site_name":"MaaT Pharma","article_published_time":"2022-03-17T17:04:40+00:00","article_modified_time":"2023-09-25T13:52:56+00:00","og_image":[{"width":2362,"height":2362,"url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","type":"image\/png"}],"author":"MaaT Pharma","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"MaaT Pharma","Dur\u00e9e de lecture estim\u00e9e":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/#article","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/"},"author":{"name":"MaaT Pharma","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"MaaT Pharma pr\u00e9sentera des donn\u00e9es cliniques prometteuses pour MaaT013, son candidat-m\u00e9dicament le plus avanc\u00e9, lors de la 48\u00e8me rencontre annuelle de l\u2019EBMT","datePublished":"2022-03-17T17:04:40+00:00","dateModified":"2023-09-25T13:52:56+00:00","mainEntityOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/"},"wordCount":2294,"publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/","url":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/","name":"MaaT Pharma pr\u00e9sentera des donn\u00e9es cliniques prometteuses pour MaaT013, son candidat-m\u00e9dicament le plus avanc\u00e9, lors de la 48\u00e8me rencontre annuelle de l\u2019EBMT - MaaT Pharma","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/#primaryimage"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","datePublished":"2022-03-17T17:04:40+00:00","dateModified":"2023-09-25T13:52:56+00:00","breadcrumb":{"@id":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/#primaryimage","url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","contentUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presentera-des-donnees-cliniques-prometteuses-pour-maat013-son-candidat-medicament-le-plus-avance-lors-de-la-48eme-rencontre-annuelle-de-lebmt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/maat.swebwp.oci.eu\/fr\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma pr\u00e9sentera des donn\u00e9es cliniques prometteuses pour MaaT013, son candidat-m\u00e9dicament le plus avanc\u00e9, lors de la 48\u00e8me rencontre annuelle de l\u2019EBMT"}]},{"@type":"WebSite","@id":"https:\/\/maat.swebwp.oci.eu\/#website","url":"https:\/\/maat.swebwp.oci.eu\/","name":"MaaT Pharma","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/maat.swebwp.oci.eu\/#organization","name":"Maat Pharma","url":"https:\/\/maat.swebwp.oci.eu\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"MaaT Pharma"}]}},"_links":{"self":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/7224","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/comments?post=7224"}],"version-history":[{"count":0,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/7224\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media\/7120"}],"wp:attachment":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media?parent=7224"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/categories?post=7224"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/tags?post=7224"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/category_press?post=7224"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/year_press?post=7224"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}